Gossamer Bio, Inc. (NASDAQ:GOSS) shares traded lower Friday as investors weighed a structured private placement offering up to $250 million in financing tied to key FDA milestones for seralutinib.
The pullback followed an earlier premarket surge, when Gossamer Bio jumped 31.55% to 21 cents, with a market capitalization of about $76.9 million.
Gossamer Bio Secures Up To $250 Million
Gossamer Bio announced a structured private placement expected to provide up to $250 million in gross proceeds.
The financing includes $150 million of committed capital to help fund seralutinib through a potential FDA approval pathway.
